Genetic Polymorphisms
6
2
2
1
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 6 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 1 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (6)
Impact of Genetic Polymorphisms And DASH Diet On Weight Loss Progression In Climacteric Women With Metabolic Syndrome
Effect of Genetic Polymorphisms on the Clinical Response to SGLT2 Inhibitors in Heart Failure Patients
Influence of Pelacarsen on Patients After Myocardial Infarction With High Lp(a) Values (PEMILA)
Markers of Cardiovascular Risk in Patients With Premature Coronary Artery Disease and Treatment
NIEHS/UNC Environmental Polymorphism Study
Developing Individualized Strategies to Prevent Nausea and Vomiting